Skip to main content
. Author manuscript; available in PMC: 2019 Oct 30.
Published in final edited form as: Clin Cancer Res. 2019 Jul 15;25(19):5752–5758. doi: 10.1158/1078-0432.CCR-18-3453

Table 2.

Treatment-Related Toxicity

All treated patients (N=12)
Grade 1 Grade 2 Total
Any treatment-related adverse event 5 (42%) 3 (25%) 8 (67%)
Diarrhea 5 (42%) 1 (8%) 6 (50%)
Fatigue 1 (8%) 1 (8%) 2 (17%)
Dermatitis acneiform 2 (17%) - 2 (17%)
Mucosal inflammation 1 (8%) - 1 (8%)
Folliculitis 1 (8%) - 1 (8%)
Tinea cruris 1 (8%) - 1 (8%)
Myalgia 1 (8%) - 1 (8%)
Dysgeusia - 1 (8%) 1 (8%)
Headache 1 (8%) - 1 (8%)
Oropharyngeal pain 1 (8%) - 1 (8%)
Sinus Congestion 1 (8%) - 1 (8%)
Flushing 1 (8%) - 1 (8%)

All treatment-related toxicity was ≤ grade 2. Data are shown as n (%).